Biotech company Biogen (NASDAQ:BIIB) in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed ...

Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries. According to the Food ...

Biogen Inc. (BIIB) reported $2.43 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 6.1%. EPS of $3.02 for the same period compares to $3.67 a year ago.

Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a breakdown of recent ...

Good morning. My name is Melinda, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Biogen First Quarter 2025 Earnings Call and Business Update. All ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...

I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Despite representing great value from an ...